David Hutton

According to the company, the deals from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024.

A University of Houston professor found that the excitement over the results of LLR as a treatment option for patients with myopia may have come too soon, before its efficacy was confirmed. One company is taking exception with the study.

Wilmer's expansive focus and deep bench are advancing the understanding of artificial intelligence tools and potential ophthalmic applications.

The licensing deal includes upfront, development milestones, and sales royalties, with additional considerations throughout the term of the agreement.

Sanders is affiliated with the Retina Group of Washington (RGW) and PRISM Vision Group. He is the first African American and the first PRISM-affiliated physician to serve as president of the ASRS.

Researchers at Mass Eye and Ear have demonstrated that retinal imaging can help predict a person’s risk of developing ocular, neuropsychiatric, cardiac, metabolic, and pulmonary diseases.

LambdaVision is leveraging the microgravity environment of the space station to develop higher-quality implants than is currently possible on Earth.

ACDN-01 is the first-ever RNA exon editor to enter clinical development and the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease. Ascidian expects to initiate enrollment in Phase 1/2 STELLAR study in the first half of 2024.

David Hutton of Ophthalmology Times talks with Jeffrey Cleland, PhD, President and CEO of Ashvattha Therapeutics, about the company's D-4517.2, a unique nanomedicine technology for the treatment of wet AMD and DME.

According to researchers at Johns Hopkins Children’s Center, AI-driven cameras take images of the back of the eye and require no eye drops can be used to close care gaps.

According to the company, favorable safety and tolerability profiles were observed with the first 2 SPVN06 doses across 6 patients. The exploration of SPVN06 in geographic geographic atrophy is set to begin in 2024.

According to the company, the research is being conducted in collaboration with London-based Imperial College Healthcare NHS Trust.

The new contact lenses contain micro-sensors which monitor changes in IOP over a period of several hours, sending the data collected wirelessly so it can be analyzed by an ophthalmologist and a diagnosis given.

According to the companies, the deal also includes Coherus’ CIMERLI biologics license application, ophthalmology sales and select field reimbursement teams. Coherus will now focus on its oncology business.

Researchers are unveiling results show previously unknown inherited genetic variants that contribute to primary open-angle glaucoma, the most common form of the disease.

The combined organization will support all aspects of ophthalmic clinical research, from front of the eye to back of the eye, leveraging an even larger team of experts with centuries of collective experience in ophthalmology.

Legislators in New Hampshire, Missouri, West Virginia are among states considering amendments to the regulation of optometry.

Allen Ho, MD, FACS, FASRS, will make a presentation at the meeting, to be held virtually on February 3.

According to the company, ABBV-RGX-314 continues to be well tolerated in over 100 patients from three dose levels with no drug-related serious adverse events. The new data was presented at the Hawaiian Eye and Retina meeting in Maui, by John Pitcher, MD, and includes 6-month results from two additional dose level 3 cohorts.

Swiss Ophthalmology Innovation (Sophi) is a phaco technology providing mobility, simplicity, and safety within the operating field.

TRS01 ophthalmic solution is targeted for the treatment of non-infectious uveitis, including uveitic glaucoma.

NIDEK Co. Ltd. has made a financial donation to Orbis International to support Orbis’s artificial intelligence (AI)-based screening services in Vietnam.

According to the company, MicroPine, currently in late phase III for pediatric progressive myopia, will complement Eyenovia’s commercial-stage asset, Mydcombi, as well as its pre-PDUFA candidate, APP13007.

David Hutton of Ophthalmology Times talks with Eric Donnenfeld, MD about his presentation "Small Aperture IOL for Irregular Corneas" at this year's Hawaiian Eye and Retina 2024 Meeting.

According to the Advanced Research Projects Agency for Health, its program aims to transplant human eyes and reestablish visual connection to the brain.

David Hutton of Ophthalmology Times talks with William Trattler, MD, about his presentation "Toric IOL pearls for Correcting Lower Levels of Astigmatism" at this year's Hawaiian Eye and Retina 2024 Meeting.

David Hutton of Ophthalmology Times talks with Andrew Lee, MD, about his presentation "Neuro op mimics of thyroid eye disease" at this year's Hawaiian Eye and Retina 2024 Meeting.

According to a study by Johns Hopkins Children’s Center researchers, AI-driven cameras that take images of the back of the eye and require no eye drops can be used to close care gaps.